RxDoctor Payments Data

Shah-Hinan Ahmed, MD

Interventional Cardiology · San Antonio, TXNPI 1245262377

Payments from drug & device makers

$132,962in general payments, 2019–2025

Across 605 payments — averaging $219.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$64K
  • Abbott$27K
  • Cardiovascular Systems Inc.$20K
  • AstraZeneca$6K
  • Penumbra, Inc.$3K
  • Amgen$2K
  • plus $10K from 48 others

What the payments were for

  • Consulting fees$18,99517%
  • Speaking & faculty fees$59,47553%
  • Travel & lodging$13,76612%
  • Food & beverage$20,43518%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$132,962 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$112,651
Medicare patients
401
Services billed
1,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$57,939
EntrestoSacubitril/Valsartan38$42,087
BrilintaTicagrelor24$20,797
XareltoRivaroxaban12$18,045
Metoprolol Succinate65$765
Atorvastatin Calcium77$724
Rosuvastatin Calcium37$682
Furosemide49$541
Carvedilol76$427
Metoprolol Tartrate69$356
ClopidogrelClopidogrel Bisulfate30$304
Amlodipine Besylate59$284
Isosorbide Mononitrate ErIsosorbide Mononitrate17$265
Lisinopril29$203
Losartan Potassium33$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$141$57,93958 claims
NovartisEntresto$159$42,08738 claims
AstraZenecaBrilinta$5,632$20,79724 claims
Johnson & JohnsonXarelto$897$18,04512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →